Upadacitinib shows 94.1% remission at 26 weeks in Crohn's disease cohort
Study compares upadacitinib and other therapies for Crohn's disease remission
This retrospective cohort study of 218 individuals with Crohn's disease found a 94.1% clinical remission rate at 26 weeks for upadacitinib, …
Upadacitinib showed a 94.1% remission rate for Crohn's disease patients at 26 weeks, but this finding comes from a very small group of just …
Hospitalized AE-RA-ILD patients receiving JAK inhibitors alongside glucocorticoids showed mixed respiratory outcomes over three months.
A Rheumatoid Arthritis Drug May Help Save Lungs in Crisis
This retrospective observational case series examined six consecutive patients hospitalized for acute exacerbation of rheumatoid arthritis–a…
A small study suggests a familiar arthritis pill may help calm sudden, dangerous lung flare-ups in people with rheumatoid arthritis.
Meta-analysis finds oral JAK inhibitors increase HDL and LDL cholesterol levels in patients from RCTs
Common arthritis and skin drugs linked to cholesterol changes, analysis finds
A systematic review and meta-analysis of 13 phase 2 and 3 RCTs involving 5,658 patients found treatment with oral JAK inhibitors (baricitini…
Common arthritis and skin drugs can raise both 'good' and 'bad' cholesterol levels, a review of nearly 4,000 patients shows.
Network meta-analysis ranks upadacitinib highest for efficacy in moderate-to-severe atopic dermatitis
Study compares eczema medications, finds upadacitinib 30 mg ranked highest for effectiveness
A network meta-analysis of 16,334 adults with moderate-to-severe atopic dermatitis compared approved systemic targeted therapies. Upadacitin…
Upadacitinib 30 mg ranked highest for clearing skin and reducing itch among approved eczema medications in a new analysis of over 16,000 pat…